1
|
Bogado Lopes J, Senko AN, Bahnsen K, Geisler D, Kim E, Bernanos M, Cash D, Ehrlich S, Vernon AC, Kempermann G. Individual behavioral trajectories shape whole-brain connectivity in mice. eLife 2023; 12:e80379. [PMID: 36645260 PMCID: PMC9977274 DOI: 10.7554/elife.80379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 01/13/2023] [Indexed: 01/17/2023] Open
Abstract
It is widely assumed that our actions shape our brains and that the resulting connections determine who we are. To test this idea in a reductionist setting, in which genes and environment are controlled, we investigated differences in neuroanatomy and structural covariance by ex vivo structural magnetic resonance imaging in mice whose behavioral activity was continuously tracked for 3 months in a large, enriched environment. We confirmed that environmental enrichment increases mouse hippocampal volumes. Stratifying the enriched group according to individual longitudinal behavioral trajectories, however, revealed striking differences in mouse brain structural covariance in continuously highly active mice compared to those whose trajectories showed signs of habituating activity. Network-based statistics identified distinct subnetworks of murine structural covariance underlying these differences in behavioral activity. Together, these results reveal that differentiated behavioral trajectories of mice in an enriched environment are associated with differences in brain connectivity.
Collapse
Affiliation(s)
- Jadna Bogado Lopes
- German Center for Neurodegenerative Diseases (DZNE) DresdenDresdenGermany
- Center for Regenerative Therapies Dresden (CRTD), TU DresdenDresdenGermany
| | - Anna N Senko
- German Center for Neurodegenerative Diseases (DZNE) DresdenDresdenGermany
- Center for Regenerative Therapies Dresden (CRTD), TU DresdenDresdenGermany
| | - Klaas Bahnsen
- Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of MedicineDresdenGermany
| | - Daniel Geisler
- Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of MedicineDresdenGermany
| | - Eugene Kim
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience King's CollegeLondonUnited Kingdom
| | - Michel Bernanos
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience King's CollegeLondonUnited Kingdom
| | - Diana Cash
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience King's CollegeLondonUnited Kingdom
| | - Stefan Ehrlich
- Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of MedicineDresdenGermany
- Department of Child and Adolescent Psychiatry, Faculty of Medicine, Eating Disorder Treatment and Research CenterDresdenGermany
| | - Anthony C Vernon
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's CollegeLondonUnited Kingdom
- MRC Centre for Neurodevelopmental Disorders, King's CollegeLondonUnited Kingdom
| | - Gerd Kempermann
- German Center for Neurodegenerative Diseases (DZNE) DresdenDresdenGermany
- Center for Regenerative Therapies Dresden (CRTD), TU DresdenDresdenGermany
| |
Collapse
|
2
|
Gelegen C, Cash D, Ilic K, Sander M, Kim E, Simmons C, Bernanos M, Lama J, Randall K, Brown JT, Kalanj-Bognar S, Cooke S, Ray Chaudhuri K, Ballard C, Francis P, Rosenzweig I. Relevance of sleep and associated structural changes in GBA1 mouse to human rapid eye movement behavior disorder. Sci Rep 2022; 12:7973. [PMID: 35562385 PMCID: PMC9105586 DOI: 10.1038/s41598-022-11516-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 04/22/2022] [Indexed: 11/29/2022] Open
Abstract
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a REM parasomnia that often predicts the later occurrence of alpha-synucleinopathies. Variants in the gene encoding for the lysosomal enzyme glucocerebrosidase, GBA, strongly increase the risk of RBD. In a GBA1-mouse model recently shown to mimic prodromal stages of α-synucleinopathy, we now demonstrate striking REM and NREM electroencephalographic sleep abnormalities accompanied by distinct structural changes in the more widespread sleep neurocircuitry.
Collapse
Affiliation(s)
- Cigdem Gelegen
- Department of Neuroimaging, Sleep and Brain Plasticity Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK
- Basic and Clinical Neuroscience, IoPPN, KCL, London, UK
| | - Diana Cash
- Department of Neuroimaging, Sleep and Brain Plasticity Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK
- BRAIN, Department of Neuroimaging, KCL, London, UK
| | - Katarina Ilic
- Department of Neuroimaging, Sleep and Brain Plasticity Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK
- Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia
| | - Millie Sander
- College of Medicine and Health, University of Exeter, Exeter, UK
| | - Eugene Kim
- BRAIN, Department of Neuroimaging, KCL, London, UK
| | | | | | - Joana Lama
- Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Diseases, Guy's Campus, KCL, London, UK
| | | | - Jonathan T Brown
- College of Medicine and Health, University of Exeter, Exeter, UK
| | - Svjetlana Kalanj-Bognar
- Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia
| | - Samuel Cooke
- Basic and Clinical Neuroscience, IoPPN, KCL, London, UK
| | - K Ray Chaudhuri
- King's College London and Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK
| | - Clive Ballard
- College of Medicine and Health, University of Exeter, Exeter, UK
| | - Paul Francis
- College of Medicine and Health, University of Exeter, Exeter, UK
- Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Diseases, Guy's Campus, KCL, London, UK
| | - Ivana Rosenzweig
- Department of Neuroimaging, Sleep and Brain Plasticity Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), De Crespigny Park, Box 089, London, SE5 8AF, UK.
- Sleep Disorders Centre, GSTT, London, UK.
| |
Collapse
|
3
|
Duricki DA, Drndarski S, Bernanos M, Wood T, Bosch K, Chen Q, Shine HD, Simmons C, Williams SCR, McMahon SB, Begley DJ, Cash D, Moon LDF. Stroke Recovery in Rats after 24-Hour-Delayed Intramuscular Neurotrophin-3 Infusion. Ann Neurol 2018; 85:32-46. [PMID: 30525223 PMCID: PMC6492080 DOI: 10.1002/ana.25386] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Revised: 11/28/2018] [Accepted: 11/28/2018] [Indexed: 12/30/2022]
Abstract
Objective Neurotrophin‐3 (NT3) plays a key role in the development and function of locomotor circuits including descending serotonergic and corticospinal tract axons and afferents from muscle and skin. We have previously shown that gene therapy delivery of human NT3 into affected forelimb muscles improves sensorimotor recovery after stroke in adult and elderly rats. Here, to move toward the clinic, we tested the hypothesis that intramuscular infusion of NT3 protein could improve sensorimotor recovery after stroke. Methods Rats received unilateral ischemic stroke in sensorimotor cortex. To simulate a clinically feasible time to treatment, 24 hours later rats were randomized to receive NT3 or vehicle by infusion into affected triceps brachii for 4 weeks using implanted catheters and minipumps. Results Radiolabeled NT3 crossed from the bloodstream into the brain and spinal cord in rodents with or without strokes. NT3 increased the accuracy of forelimb placement during walking on a horizontal ladder and increased use of the affected arm for lateral support during rearing. NT3 also reversed sensory impairment of the affected wrist. Functional magnetic resonance imaging during stimulation of the affected wrist showed spontaneous recovery of peri‐infarct blood oxygenation level–dependent signal that NT3 did not further enhance. Rather, NT3 induced neuroplasticity of the spared corticospinal and serotonergic pathways. Interpretation Our results show that delayed, peripheral infusion of NT3 can improve sensorimotor function after ischemic stroke. Phase I and II clinical trials of NT3 (for constipation and neuropathy) have shown that peripheral high doses are safe and well tolerated, which paves the way for NT3 as a therapy for stroke. ANN NEUROL 2019;85:32–46.
Collapse
Affiliation(s)
- Denise A Duricki
- Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom.,Centre for Integrative Biology, King's College London, London, United Kingdom
| | - Svetlana Drndarski
- Blood-Brain Barrier Group, Institute of Pharmaceutical Science, King's College London, London, United Kingdom
| | - Michel Bernanos
- Neuroimaging Research Group, King's College London, London, United Kingdom
| | - Tobias Wood
- Neuroimaging Research Group, King's College London, London, United Kingdom
| | - Karen Bosch
- Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
| | - Qin Chen
- Center for Cell and Gene Therapy, Department of Neuroscience, Baylor College of Medicine, Houston, TX
| | - H David Shine
- Center for Cell and Gene Therapy, Department of Neuroscience, Baylor College of Medicine, Houston, TX
| | - Camilla Simmons
- Neuroimaging Research Group, King's College London, London, United Kingdom
| | | | - Stephen B McMahon
- Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
| | - David J Begley
- Blood-Brain Barrier Group, Institute of Pharmaceutical Science, King's College London, London, United Kingdom
| | - Diana Cash
- Neuroimaging Research Group, King's College London, London, United Kingdom
| | - Lawrence D F Moon
- Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom.,Centre for Integrative Biology, King's College London, London, United Kingdom
| |
Collapse
|
4
|
Tomimatsu Y, Cash D, Suzuki M, Suzuki K, Bernanos M, Simmons C, Williams SC, Kimura H. TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge. Neuroscience 2016; 339:180-190. [DOI: 10.1016/j.neuroscience.2016.10.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Revised: 09/30/2016] [Accepted: 10/02/2016] [Indexed: 02/06/2023]
|
5
|
Duricki DA, Hutson TH, Kathe C, Soleman S, Gonzalez-Carter D, Petruska JC, Shine HD, Chen Q, Wood TC, Bernanos M, Cash D, Williams SCR, Gage FH, Moon LDF. Delayed intramuscular human neurotrophin-3 improves recovery in adult and elderly rats after stroke. Brain 2015; 139:259-75. [PMID: 26614754 PMCID: PMC4785394 DOI: 10.1093/brain/awv341] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Accepted: 09/29/2015] [Indexed: 12/11/2022] Open
Abstract
There is an urgent need for a therapy that reverses disability after stroke when initiated in a time frame suitable for the majority of new victims. We show here that intramuscular delivery of neurotrophin-3 (NT3, encoded by NTF3) can induce sensorimotor recovery when treatment is initiated 24 h after stroke. Specifically, in two randomized, blinded preclinical trials, we show improved sensory and locomotor function in adult (6 months) and elderly (18 months) rats treated 24 h following cortical ischaemic stroke with human NT3 delivered using a clinically approved serotype of adeno-associated viral vector (AAV1). Importantly, AAV1-hNT3 was given in a clinically-feasible timeframe using a straightforward, targeted route (injections into disabled forelimb muscles). Magnetic resonance imaging and histology showed that recovery was not due to neuroprotection, as expected given the delayed treatment. Rather, treatment caused corticospinal axons from the less affected hemisphere to sprout in the spinal cord. This treatment is the first gene therapy that reverses disability after stroke when administered intramuscularly in an elderly body. Importantly, phase I and II clinical trials by others show that repeated, peripherally administered high doses of recombinant NT3 are safe and well tolerated in humans with other conditions. This paves the way for NT3 as a therapy for stroke.
Collapse
Affiliation(s)
- Denise A Duricki
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 2 Centre for Integrative Biology, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK
| | - Thomas H Hutson
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 3 Division of Brain Sciences, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK
| | - Claudia Kathe
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK
| | - Sara Soleman
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 4 John Van Geest Centre for Brain Repair University of Cambridge, The E.D. Adrian Building, Forvie Site, Robinson Way Cambridge, CB2 0PY, UK
| | - Daniel Gonzalez-Carter
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 3 Division of Brain Sciences, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK
| | - Jeffrey C Petruska
- 5 Department of Anatomical Sciences and Neurobiology, University of Louisville; Kentucky Spinal Cord Injury Research Center, Department of Neurological Surgery, Louisville, Kentucky, USA
| | - H David Shine
- 6 Center for Cell and Gene Therapy, Department of Neuroscience, Alkek Bldg N1130.01, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
| | - Qin Chen
- 6 Center for Cell and Gene Therapy, Department of Neuroscience, Alkek Bldg N1130.01, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
| | - Tobias C Wood
- 7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK
| | - Michel Bernanos
- 7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK
| | - Diana Cash
- 7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK
| | - Steven C R Williams
- 7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK
| | - Fred H Gage
- 8 The Salk Institute for Biological Studies, 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
| | - Lawrence D F Moon
- 1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 2 Centre for Integrative Biology, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK
| |
Collapse
|
6
|
Ashioti M, Beech JS, Lowe AS, Bernanos M, McCreary A, Modo MM, Williams SCR. Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT(1A) agonist in rat models of ischaemic stroke. BMC Neurosci 2009; 10:82. [PMID: 19607699 PMCID: PMC2720976 DOI: 10.1186/1471-2202-10-82] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2009] [Accepted: 07/16/2009] [Indexed: 02/01/2023] Open
Abstract
Background 5HT1A agonists have previously been shown to promote recovery in animal models of stroke using ex vivo outcome measures which have raised the hopes for a potential clinical implementation. The purpose of this study was to evaluate the potential neuroprotective properties of a novel 5HT1A agonist DU123015 in 2 different models of transient focal ischaemic stroke of varying severities using both in vivo neuroimaging and behavioural techniques as primary outcome measures. For these studies, the NMDA receptor antagonist MK-801 was also utilized as a positive control to further assess the effectiveness of the stroke models and techniques used. Results In contrast to MK-801, no significant therapeutic effect of DU123015 on lesion volume in either the distal MCAo or intraluminal thread model of stroke was found. MK-801 significantly reduced lesion volume in both models; the mild distal MCAo condition (60 min ischaemia) and the intraluminal thread model, although it had no significant impact upon the lesion size in the severe distal MCAo condition (120 min ischaemia). These therapeutic effects on lesion size were mirrored on a behavioural test for sensory neglect and neurological deficit score in the intraluminal thread model. Conclusion This study highlights the need for a thorough experimental design to test novel neuroprotective compounds in experimental stroke investigations incorporating: a positive reference compound, different models of focal ischaemia, varying the duration of ischaemia, and objective in vivo assessments within a single study. This procedure will help us to minimise the translation of less efficacious compounds.
Collapse
Affiliation(s)
- Maria Ashioti
- Institute of Psychiatry, Kings College London, Denmark Hill, UK.
| | | | | | | | | | | | | |
Collapse
|